Sansure Biotech vs MeHow Innovative Ltd. A: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sansure Biotech Inc (688289.CG)

Q3 202615 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.

August 202615 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.

Latest15 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.

MeHow Innovative Ltd. A (301363.CS)

Q3 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

August 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Latest27 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.